Umbilical cord mesenchymal stem cell based on microRNA modification, exosome of umbilical cord mesenchymal stem cell and application of umbilical cord mesenchymal stem cell

By designing the miR-210 mutant sequence and introducing it into umbilical cord mesenchymal stem cells using a recombinant vector, the problems of low delivery efficiency and short-lasting effects were solved, achieving efficient tissue repair and nerve function recovery, thus overcoming a key bottleneck in the clinical application of umbilical cord mesenchymal stem cells.

CN122326596APending Publication Date: 2026-07-03SHANGHAI ZHIQUAN BIOTECHNOLOGY CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
CN202610320516.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-17
Publication Date
2026-07-03

AI Technical Summary

Technical Problem

In existing technologies, umbilical cord mesenchymal stem cells suffer from low in vivo survival rate, insufficient homing efficiency, and functional heterogeneity in clinical applications. miRNA modification strategies suffer from low delivery efficiency and short-lasting effects, and there is a lack of effective functional verification systems.

Method used

By designing miR-210 mutant sequences and introducing them into umbilical cord mesenchymal stem cells using recombinant vectors (such as lentiviral vectors), miRNA delivery and expression are optimized, exosome encapsulation efficiency and targeting are improved, key therapeutic pathways are activated, and angiogenesis and tissue repair are promoted.

Benefits of technology

It significantly improved the therapeutic efficacy of exosomes, demonstrating excellent therapeutic effects in various disease models, including improvements in myocardial ischemia, diabetic skin trauma, and cerebral ischemia models, achieving more efficient tissue repair and neurological function recovery.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to an umbilical cord mesenchymal stem cell based on microRNA modification and an exosome and application thereof. The invention provides an umbilical cord mesenchymal stem cell based on a miR-210 mutant and an exosome treatment technology of the umbilical cord mesenchymal stem cell. A miR-210 sequence is specifically modified to obtain a mutant with enhanced stability and targeting efficiency, and an exosome for highly expressing the mutant can be prepared after the mutant is introduced into umbilical cord mesenchymal stem cells. The exosome shows remarkable curative effects in various disease models, including promotion of angiogenesis, acceleration of wound repair and neuroprotection. The invention also protects a mutant sequence, a recombinant vector, a recombinant cell and a preparation method thereof, and application of the exosome in preparation of drugs for treating ischemic diseases and tissue damage. According to the technology, a new solution is provided for tissue repair by optimizing the sequence and the delivery system of the miR-210.
Need to check novelty before this filing date? Find Prior Art